Abstract
It is now well-established that human papillomavirus (HPV)-associated squamous cell carcinoma, which comprises an increasing proportion of all oropharyngeal cancers, represents a unique entity with distinct clinical and molecular characteristics. Data also has emerged demonstrating that patients with HPVpositive head and neck cancer have an improved prognosis compared to their HPV-negative counterparts, with several series showing that patients with HPV-related tumors arising from the oropharynx have at least half the risk of death. However, these studies have been complicated by such factors as the limited quality of data, small sample sizes, as well as the variability in treatment, inclusion criteria, and follow-up. Although the exact reason for the improved survival among HPV-positive patients is unclear, many investigators have proposed that HPV-related head and neck cancer is more sensitive to the effects of radiation therapy than HPVnegative tumors arising in the setting of traditional environmental exposures. Despite the attractiveness of this hypothesis, the data focusing on possible de-intensification approaches remains preliminary, and treatment paradigms will likely continue to evolve as findings from innovative clinical trials yield answers to many provocative questions.
Keywords: Cancer, head and neck, HPV, radiation, squamous cell.
Current Cancer Therapy Reviews
Title:Evolving Treatment Paradigms for HPV-Related Oropharynx Cancer
Volume: 10 Issue: 4
Author(s): Allen M. Chen, Deborah Wong and Maie St. John
Affiliation:
Keywords: Cancer, head and neck, HPV, radiation, squamous cell.
Abstract: It is now well-established that human papillomavirus (HPV)-associated squamous cell carcinoma, which comprises an increasing proportion of all oropharyngeal cancers, represents a unique entity with distinct clinical and molecular characteristics. Data also has emerged demonstrating that patients with HPVpositive head and neck cancer have an improved prognosis compared to their HPV-negative counterparts, with several series showing that patients with HPV-related tumors arising from the oropharynx have at least half the risk of death. However, these studies have been complicated by such factors as the limited quality of data, small sample sizes, as well as the variability in treatment, inclusion criteria, and follow-up. Although the exact reason for the improved survival among HPV-positive patients is unclear, many investigators have proposed that HPV-related head and neck cancer is more sensitive to the effects of radiation therapy than HPVnegative tumors arising in the setting of traditional environmental exposures. Despite the attractiveness of this hypothesis, the data focusing on possible de-intensification approaches remains preliminary, and treatment paradigms will likely continue to evolve as findings from innovative clinical trials yield answers to many provocative questions.
Export Options
About this article
Cite this article as:
M. Chen Allen, Wong Deborah and St. John Maie, Evolving Treatment Paradigms for HPV-Related Oropharynx Cancer, Current Cancer Therapy Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/157339471004150407140835
DOI https://dx.doi.org/10.2174/157339471004150407140835 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Implementation of “Quality by Design (QbD)” Approach for the Development of 5-Fluorouracil Loaded Thermosensitive Hydrogel
Current Drug Delivery Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry The Use of Inorganic Compounds in Photodynamic Therapy: Improvements in Methods and Photosensitizer Design
Recent Patents on Nanotechnology Inhibition of Membrane Fusion as a Target for Antiviral Therapy
Anti-Infective Agents in Medicinal Chemistry Immunological and Translational Aspects of Glycolytic Metabolism in Various Human Tumor Entities
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy